^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    1d
    Carolyn-USA: A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=144, Recruiting, Engeneic Pty Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    gemcitabine • albumin-bound paclitaxel
    1d
    HCB101-201: Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=500, Active, not recruiting, FBD Biologics Limited | Recruiting --> Active, not recruiting | N=150 --> 500
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • carboplatin • 5-fluorouracil • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Loqtorzi (toripalimab-tpzi) • capecitabine • albumin-bound paclitaxel • Cyramza (ramucirumab) • oxaliplatin • etoposide IV • irinotecan • leucovorin calcium • HCB101
    2d
    Adebrelimab Neoadjuvant Treatment for Resectable ESCC (clinicaltrials.gov)
    P=N/A, N=22, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    cisplatin • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • AiRuiLi (adebrelimab)
    2d
    Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Dec 2026
    Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel • metformin
    3d
    PIK3CA-Mutant Non-Small Cell Lung Cancer Refractory to Two Lines of Chemoimmunotherapy: A Case Report. (PubMed, Cureus)
    Despite first-line carboplatin, nab-paclitaxel, and pembrolizumab followed by second-line carboplatin, pemetrexed, nivolumab, and ipilimumab, the disease progressed rapidly, and the patient died four months after diagnosis. This case illustrates that isolated PIK3CA-mutant NSCLC can be highly refractory to conventional chemoimmunotherapy, including regimens incorporating a cytotoxic T-lymphocyte-associated antigen 4 inhibitor. Further clinical investigation of PI3K-targeted therapies is warranted to establish effective treatment strategies for PIK3CA-mutant NSCLC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PIK3CA mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    3d
    Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P2, N=126, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • falbikitug (AZD0171)
    3d
    A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer (clinicaltrials.gov)
    P3, N=524, Not yet recruiting, FutureGen Biopharmaceutical (Beijing) Co., Ltd
    New P3 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    gemcitabine • albumin-bound paclitaxel
    3d
    Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Lenvima (lenvatinib) • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    4d
    Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Shanghai Chest Hospital | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Oct 2026
    Enrollment closed • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel
    4d
    Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel. (PubMed, Nat Commun)
    Genetic ablation of Trem2 or pharmacologic targeting with antisense oligonucleotides suppress paclitaxel-induced breast cancer lung metastasis in vivo. Collectively, our findings demonstrate that paclitaxel, but not nab-paclitaxel, stimulates TREM2 expression and expands TREM2+ macrophages, suggesting that TREM2 targeting could enhance paclitaxel efficacy while limiting metastasis.
    Journal
    |
    FGF2 (Fibroblast Growth Factor 2) • ATF3 (Activating Transcription Factor 3) • EGR1 (Early Growth Response 1) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
    |
    albumin-bound paclitaxel
    4d
    SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2/3, N=30, Recruiting, Second Affiliated Hospital of Nanchang University | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Apr 2025
    Enrollment open • Trial initiation date
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    5d
    TD-NEOE3V3: Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=390, Not yet recruiting, Tang-Du Hospital | Initiation date: May 2025 --> Feb 2026
    Trial initiation date
    |
    cisplatin • docetaxel • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel